0000899243-21-039183.txt : 20211005 0000899243-21-039183.hdr.sgml : 20211005 20211005160521 ACCESSION NUMBER: 0000899243-21-039183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211001 FILED AS OF DATE: 20211005 DATE AS OF CHANGE: 20211005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON DAVID LEE CENTRAL INDEX KEY: 0001733883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 211306647 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS STREET 2: 171 OYSTER POINT BLVD, STE. 300 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001733883 JOHNSON DAVID LEE C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO, CA 94080 0 1 0 0 Chief Commercial Officer Common Stock 2021-10-01 4 M 0 4375 A 41242 D Common Stock 2021-10-01 4 F 0 2170 26.25 D 39072 D Restricted Stock Units 2021-10-01 4 M 0 4375 0.00 D Common Stock 4375 4375 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. /s/ Miguel Carrillo, as Attorney-in-Fact 2021-10-05